• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Cellusion Inc.

Monday, June 03, 2024
CP
Cell and Gene Therapy and Genome Editing
Cellusion is a Japanese regenerative medicine start-up from Keio University, School of Medicine in Japan. The first pipeline CLS001 is aim to solve the global blindness issue around corneal transplantation. Cellusion has several unique technologies including highly efficient direct differentiation induction method to produce corneal endothelial substituted cells from iPS cells. Cellusion‘s lead program coded asCLS001 is targeting Bullous Keratopathy which is a major corneal endothelial disease currently treated only by corneal transplantation. The First-in-human investigator-initiated clinical study of CLS001 is undergoing in Keio university hospital. And, Cellusion is now under preparation of company sponsored clinical trials both in Japan the USA.
Cellusion Inc.
Company Website: https://cellusion.jp/en/
Lead Product in Development: CLS001
Number Of Unlicensed Products (For Which You Are Seeking Partners): 3

Company HQ City

Chuo

Company HQ State

Tokyo

Company HQ Country

Japan

CEO/Top Company Official

Shin Hatou, M.D., Ph.D.

Development Phase of Primary Product

Phase I
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS